- Home
- IVVD vs RDZN Comparison
IVVD vs RDZN Comparison
Compare IVVD & RDZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- RDZN
- Stock Information
- Founded
- IVVD 2020
- RDZN 2015
- Country
- IVVD United States
- RDZN United States
- Employees
- IVVD N/A
- RDZN N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- RDZN Blank Checks
- Sector
- IVVD Health Care
- RDZN Finance
- Exchange
- IVVD Nasdaq
- RDZN Nasdaq
- Market Cap
- IVVD 63.4M
- RDZN 75.2M
- IPO Year
- IVVD 2021
- RDZN N/A
- Fundamental
- Price
- IVVD $1.34
- RDZN $0.99
- Analyst Decision
- IVVD Strong Buy
- RDZN Strong Buy
- Analyst Count
- IVVD 4
- RDZN 2
- Target Price
- IVVD $3.64
- RDZN $5.00
- AVG Volume (30 Days)
- IVVD 15.0M
- RDZN 216.8K
- Earning Date
- IVVD 11-13-2025
- RDZN 11-12-2025
- Dividend Yield
- IVVD N/A
- RDZN N/A
- EPS Growth
- IVVD N/A
- RDZN N/A
- EPS
- IVVD N/A
- RDZN N/A
- Revenue
- IVVD $46,210,000.00
- RDZN $46,230,126.00
- Revenue This Year
- IVVD $385.94
- RDZN $38.45
- Revenue Next Year
- IVVD $62.62
- RDZN $66.38
- P/E Ratio
- IVVD N/A
- RDZN N/A
- Revenue Growth
- IVVD 1941.08
- RDZN N/A
- 52 Week Low
- IVVD $0.35
- RDZN $0.68
- 52 Week High
- IVVD $2.74
- RDZN $2.99
- Technical
- Relative Strength Index (RSI)
- IVVD 66.86
- RDZN 45.90
- Support Level
- IVVD $1.05
- RDZN $0.93
- Resistance Level
- IVVD $1.45
- RDZN $1.00
- Average True Range (ATR)
- IVVD 0.19
- RDZN 0.06
- MACD
- IVVD 0.05
- RDZN 0.00
- Stochastic Oscillator
- IVVD 83.82
- RDZN 56.25
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.